UBS Group
BIOA

UBS Group’s BioAge Labs BIOA Stock Holding History

UBS Group’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Buy
69,482
+39,603
+133% +$763K ﹤0.01% 5397
2025
Q4 		$395K Sell
29,879
-7,055
-19% -$62.5K ﹤0.01% 6218
2025
Q3 		$217K Buy
36,934
+14,022
+61% +$65.7K ﹤0.01% 6626
2025
Q2 		$94.6K Buy
22,912
+5,109
+29% +$20.6K ﹤0.01% 7283
2025
Q1 		$66.9K Sell
17,803
-86,088
-83% -$398K ﹤0.01% 7358
2024
Q4 		$602K Buy
+103,891
New +$1.79M ﹤0.01% 5711

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

UBS Group's BIOA Position: Q1 2026 in Review

UBS Group increased its BioAge Labs (BIOA) stake by 133% in Q1 2026, buying an estimated $763K and bringing the position to 69,482 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #5397.

UBS Group first reported a position in BIOA in Q4 2024 and has held it in 6 quarters since. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • UBS Group held 69,482 shares of BioAge Labs worth $1.22M as of Q1 2026.
  • UBS Group bought 39,603 BioAge Labs shares in Q1 2026, an estimated $763K.
  • BioAge Labs made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5397 holding.
  • UBS Group first reported a position in BioAge Labs in Q4 2024 and has held it in 6 quarters since.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.